GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite serious adverse events in about one-third of patients, the positive results support moving forward to Phase 3 trials. Analyst Michael Schmidt set a $54 price target for GMAB, suggesting significant upside from the current $34.75 share price, supported by strong financials including a 32.3% operating profit margin. Rina-S remains investigational, with safety and effectiveness yet to be fully established.
GMAB's Rina-S ovarian cancer trial results come as Pluang's Health sector shows 61 of 100 US stocks rising today. For readers following health stocks, here is Pluang's market snapshot as of Oct 06, 2026 03:02 WIB: ADPT at USD 29.71 rose 4.80% with 100% sell orders, CYTK at USD 62.59 fell 4.59%, and TXG at USD 97.74 rose 4.53% with 73% buy orders and a typical hold time of 93 days.
Fort Technology received a notification from Nasdaq on October 13, 2026, stating it failed to meet the minimum bid price requirement of $1.00 per share over the past 30 days. The company has 180 days, until April 12, 2027, to restore its share price ...
The global mobile battery market, valued at $24.9 billion in 2025, is projected to grow to $45.95 billion by 2035, driven by rising smartphone adoption, 5G rollout, and demand for longer-lasting, fast-charging batteries. Lithium-ion batteries dominat...
SpaceX reported a strong Q3 with revenue up 161% year-over-year to $14.6 billion and a net profit of $4.4 billion, reversing last year's loss. Starlink, its satellite internet service, grew revenue by nearly 70% to $5.2 billion and added 1.6 million ...
SPIE, a leading European multi-technical services provider, has signed an agreement to acquire a 76% stake in SAR ANLAGENBAU GmbH, a major electrical engineering and automation firm based in Austria and Germany. This acquisition will enhance SPIE's p...
SPIE, a European leader in energy and communication services, has agreed to acquire a 76% stake in SAR ANLAGENBAU GmbH, a key electrical engineering and automation firm in Austria and Germany. This acquisition will broaden SPIE's service portfolio in...
